Blackstone Life Sciences announces a AML co-funding agreement with J&J

Blackstone Life Sciences (BX) announced a research and development funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor, for acute myeloid leukemia. Johnson & Johnson (JNJ) and funds managed by BXLS will jointly finance a portion of the ongoing and future clinical trials of bleximenib in AML. “This is the first time that BXLS and Johnson & Johnson have entered into a co-funding agreement,” the company stated. “We believe that bleximenib’s promising clinical data, combined with Johnson & Johnson’s deep expertise in hematologic malignancies, create a strong foundation to address critical gaps in patient care. We are excited by this agreement with Johnson & Johnson, furthering our network of global leaders to accelerate innovation across the life sciences sector,” said Dr. Nicholas Galakatos, Global Head of BXLS.